Article: Study: Frovatriptan highly effective in preventing menstrually associated migraines.(Brief Article)

2003 MAY 1 - (NewsRx.com & NewsRx.net) -- Vernalis Group, plc, the U.K.-based developer of frovatriptan, announced that the results from a large multicenter study of frovatriptan in the prophylaxis (prevention) of menstrually associated migraine (MAM) were presented at the American Academy of Neurology annual meeting.

These findings confirm the positive results announced by the company in September 2002 and underline the potential value of this additional indication for frovatriptan.

These data from the study were presented to delegates by leading migraine expert Dr. Stephen Silberstein, professor of neurology at the Thomas Jefferson Hospital in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!